Nemaura Pharma today announced it had successful completed a clinical Pharmacokinetic Study on a complex transdermal patch that was developed in-house, adding to their portfolio of complex transdermal systems that are being developed for partner companies. This paves the way for a pivotal clinical program and subsequent product registration across a number of territories. The company have been engaged with various third party licensees to develop complex Transdermal products as well as Injectable products for global markets. The company is strategically partnered with Commercial scale contract manufacturers to be able to provide a seamless service from concept to market for complex dosage forms.
Menu